EU/3/18/2120

About

On 14 December 2018, orphan designation (EU/3/18/2120) was granted by the European Commission to Takeda Pharma A/S, Denmark, for pevonedistat for the treatment of myelodysplastic syndromes.

Key facts

Active substance
Pevonedistat
Disease / condition
Treatment of myelodysplastic syndromes
Date of first decision
14/12/2018
Outcome
Positive
EU designation number
EU/3/18/2120

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Takeda Pharma A/S
Dybendal Alle 10
2630 Taastrup
Denmark
Tel. +45 46 77 1036
E-mail: info@takeda.dk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating